SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $209 | -16.7% | 7,570 | 0.0% | 0.02% | -20.0% |
| Q2 2023 | $251 | -8.4% | 7,570 | 0.0% | 0.02% | -9.1% |
| Q1 2023 | $274 | +1.5% | 7,570 | 0.0% | 0.02% | -4.3% |
| Q4 2022 | $270 | -99.9% | 7,570 | 0.0% | 0.02% | -4.2% |
| Q3 2022 | $256,000 | -5.9% | 7,570 | -10.2% | 0.02% | +14.3% |
| Q1 2022 | $272,000 | -15.0% | 8,430 | -18.8% | 0.02% | -19.2% |
| Q2 2021 | $320,000 | +17.6% | 10,380 | 0.0% | 0.03% | +4.0% |
| Q1 2021 | $272,000 | +4.2% | 10,380 | 0.0% | 0.02% | 0.0% |
| Q4 2020 | $261,000 | +20.8% | 10,380 | 0.0% | 0.02% | +4.2% |
| Q3 2020 | $216,000 | -13.6% | 10,380 | 0.0% | 0.02% | -17.2% |
| Q2 2020 | $250,000 | +33.7% | 10,380 | 0.0% | 0.03% | +11.5% |
| Q1 2020 | $187,000 | -19.4% | 10,380 | +47.9% | 0.03% | -31.6% |
| Q2 2019 | $232,000 | -5.7% | 7,020 | 0.0% | 0.04% | -11.6% |
| Q1 2019 | $246,000 | +20.0% | 7,020 | +105.3% | 0.04% | 0.0% |
| Q2 2018 | $205,000 | – | 3,420 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |